Detailed explanation of the instructions for Crizotinib/Xalkore capsules: from indications to medication precautions

Crizotinib is a representative oral small molecule tyrosine kinase inhibitor that is widely used to treat a variety of ALK-positive tumors. Since its approval, crizotinib has demonstrated good efficacy and a clear safety profile in the field of targeted therapy, especially in patients with non-small cell lung cancer (NSCLC) and has become one of the standard treatment options. According to the latest drug instructions, crizotinib is suitable for a variety of ALK or ROS1 rearrangement-positive malignant tumors, including metastatic non-small cell lung cancer, systemic anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumor (IMT).

In non-small cell lung cancer, crizotinib is used to treat adult patients whose tumors exhibitALK or ROS1 gene rearrangements. These gene rearrangements often drive abnormal tumor growth. Crizotinib inhibits the corresponding tyrosine kinase activity and blocks the signaling pathways of cancer cells, thereby achieving anti-tumor effects. Clinical studies have shown that crizotinib can significantly prolong the progression-free survival of patients, and some patients even achieve longer disease control. In the field of pediatrics and adolescents, crizotinib is also approved for the treatment of relapsed or refractory ALK-positive systemic ALCL, as well as unresectable, relapsed or refractory ALK-positive IMT. Especially in pediatric indications, the emergence of crizotinib has filled the gap that previously lacked targeted therapeutic drugs.

In terms of use restrictions, there is currently insufficient data to determine the safety and efficacy of crizotinib in the treatment of relapsed or refractory ALCL in the elderly population. Therefore, the benefits and risks need to be carefully evaluated when used in this population.

In terms of usage and dosage, crizotinib is taken orally in the form of capsules or granules. The recommended dose for adults is 250 mg twice a day. For children and adolescents, the recommended dose is 280 mg/m2 twice a day based on body surface area. It should be noted that patients should take the medicine regularly regardless of eating or not, and the capsules should not be chewed, crushed or opened. If you are unable to swallow the capsule due to special reasons, you can choose granular preparations of the corresponding dosage form. If you miss a dose and it is more than 6 hours before the next dose, you should take it as soon as possible; if it is less than 6 hours, skip the dose and do not take it twice. If vomiting occurs after taking the medicine, it is not recommended to take a supplementary dose. You should continue to take the next dose at the regular time.

In terms of safety, crizotinib may cause a series of adverse reactions, including but not limited to gastrointestinal symptoms (such as nausea, vomiting, diarrhea), visual impairment, abnormal liver function,QT interval prolongation and interstitial lung disease, etc. Liver function, electrolytes, electrocardiogram and other physiological indicators should be monitored regularly during medication. In particular, patients with underlying diseases need to closely observe drug reactions. It should be noted in particular that crizotinib interacts with a variety of drugs through metabolic channels (CYP3A), so concomitant use should be guided by a professional physician.

In summary, crizotinib, as a tyrosine kinase inhibitor targeting ALK and ROS1, not only brings precise treatment options to patients with non-small cell lung cancer, but also expands the treatment of rare pediatric tumors. With the continuous expansion of its indications and optimization of dosage forms, the clinical application prospects of crizotinib are becoming increasingly broad. However, during medication, patients and doctors should strictly follow the instructions and pay attention to the monitoring and management of adverse reactions to achieve a balance between optimal efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB08865